health pharma news today obesity drugs glp-1 Drug Market: the rapid growth of the diabetes and market World Health Organization recommends GLP-1
Description
Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome
The mechanisms underlying the favorable cardiovascular effects of GLP-1RAs remain incompletely understood
Pharmacol Ther 113:546593 Moffett RC, Patterson S, Irwin N, Flatt PR (2015) Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes
Blood withdrawal occurred approximately 24 h after the final dose
These drugs not only aid in weight loss but also offer benefits in managing comorbid conditions such as cardiovascular diseases and type 2 diabetes
